DE69527696D1 - Kristalline Paclitaxel Hydrate - Google Patents

Kristalline Paclitaxel Hydrate

Info

Publication number
DE69527696D1
DE69527696D1 DE69527696T DE69527696T DE69527696D1 DE 69527696 D1 DE69527696 D1 DE 69527696D1 DE 69527696 T DE69527696 T DE 69527696T DE 69527696 T DE69527696 T DE 69527696T DE 69527696 D1 DE69527696 D1 DE 69527696D1
Authority
DE
Germany
Prior art keywords
hydrates
crystalline paclitaxel
paclitaxel
pseudopolymorph
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527696T
Other languages
English (en)
Other versions
DE69527696T3 (de
DE69527696T2 (de
Inventor
Robert K Perrone
Scott R Stenberg
Murray A Kaplan
Akram Saab
Shreeram Agharkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23396320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69527696(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE69527696D1 publication Critical patent/DE69527696D1/de
Application granted granted Critical
Publication of DE69527696T2 publication Critical patent/DE69527696T2/de
Publication of DE69527696T3 publication Critical patent/DE69527696T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69527696T 1994-12-13 1995-12-12 Kristallines Paclitaxel-Hydrat Expired - Fee Related DE69527696T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35512594A 1994-12-13 1994-12-13
US355125 1994-12-13

Publications (3)

Publication Number Publication Date
DE69527696D1 true DE69527696D1 (de) 2002-09-12
DE69527696T2 DE69527696T2 (de) 2003-04-03
DE69527696T3 DE69527696T3 (de) 2008-04-03

Family

ID=23396320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527696T Expired - Fee Related DE69527696T3 (de) 1994-12-13 1995-12-12 Kristallines Paclitaxel-Hydrat

Country Status (9)

Country Link
EP (1) EP0717041B2 (de)
JP (1) JPH08208636A (de)
AT (1) ATE221879T1 (de)
AU (1) AU699542B2 (de)
CA (1) CA2163837C (de)
DE (1) DE69527696T3 (de)
DK (1) DK0717041T3 (de)
ES (1) ES2181744T5 (de)
PT (1) PT717041E (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2729666A1 (fr) * 1995-01-25 1996-07-26 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r, 3s)- benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy- 2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxo- tax-11-en-13alpha-yle
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP2292225B9 (de) 1997-03-31 2012-06-27 Boston Scientific Scimed Limited Darreichungsform enthaltend Taxol in kristalliner Form
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
EP1451168A4 (de) 2001-11-30 2005-08-24 Bristol Myers Squibb Co Paclitaxelsolvate
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7919108B2 (en) 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
EP2043704B2 (de) 2006-06-30 2017-04-19 Cook Medical Technologies LLC Verfahren zur herstellung und modifizierung von taxan-beschichtungen für implantierbare medizinische vorrichtungen
BRPI0806727B8 (pt) 2007-01-21 2021-06-22 Hemoteq Ag método para o revestimento de um cateter de balão
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2451496B1 (de) 2009-07-10 2015-07-22 Boston Scientific Scimed, Inc. Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
EP2453938B1 (de) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nukleierung von wirkstofffreisetzungsballons für verbesserte kristallgrösse und -dichte
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
WO2015123082A1 (en) * 2014-02-14 2015-08-20 Boston Scientific Scimed, Inc. Rapidly degrading embolic particles with therapeutic agent release

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5380916A (en) 1990-11-02 1995-01-10 University Of Florida Method for the isolation and purification of taxane derivatives
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes

Also Published As

Publication number Publication date
EP0717041B1 (de) 2002-08-07
EP0717041A1 (de) 1996-06-19
ES2181744T5 (es) 2008-03-01
CA2163837A1 (en) 1996-06-14
DE69527696T3 (de) 2008-04-03
EP0717041B2 (de) 2007-08-15
PT717041E (pt) 2002-11-29
AU4035595A (en) 1996-06-20
ES2181744T3 (es) 2003-03-01
CA2163837C (en) 1999-07-20
JPH08208636A (ja) 1996-08-13
DK0717041T3 (da) 2002-11-25
ATE221879T1 (de) 2002-08-15
AU699542B2 (en) 1998-12-03
DE69527696T2 (de) 2003-04-03

Similar Documents

Publication Publication Date Title
DE69527696D1 (de) Kristalline Paclitaxel Hydrate
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
IL140093A0 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
FI953180A0 (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
DK1200418T3 (da) Nematodicide trifluorbutener
IL114294A0 (en) Sterol derivatives
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
DE69625354D1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
CA2152771A1 (en) 7-o-ethers of taxane derivatives
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
SE9801494D0 (sv) Novel use
HUP0101482A3 (en) Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
EP1073447A4 (de) N1 modifizierte glycopeptide
SE9904128D0 (sv) Novel compounds
DE69513889T2 (de) Degradierbare Mischungszusammensetzung
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
RO116896B1 (ro) Derivaţi pseudocarbaciclinici şi procedeu pentru prepararea acestora

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee